Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Sassolas

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Bulletin Du Cancer|December 27, 2013
[Loco-regional treatments of the metastatic sites for patients with pauci-metastatic cutaneous melanoma (without brain metastasis): French national guidelines]Bruno Sassolas, Anne Mourrégot, Juliette Thariat, et al.
European Journal of Dermatology : EJD|May 29, 2010
A three-year-analysis of fixed drug eruptions in hospital settings in FranceNesrine Brahimi, Emilie Routier, Nadia Raison-Peyron, et al.
The Journal of Investigative Dermatology|January 30, 2009
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized studyPascal Joly, Jean-Claude Roujeau, Jacques Benichou, et al.
The British Journal of Dermatology|October 4, 2023
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patientsRéda Chebani, Florian Lombart, Guillaume Chaby, et al.
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|March 5, 2025
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus VulgarisBillal Tedbirt, Estelle Houivet, Maud Maho-Vaillant, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Blood|February 7, 2020
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedemaThibault Mahévas, Bertrand Arnulf, Jean-David Bouaziz, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Bulletin Du Cancer|December 27, 2013
[Loco-regional treatments of the metastatic sites for patients with pauci-metastatic cutaneous melanoma (without brain metastasis): French national guidelines]Bruno Sassolas, Anne Mourrégot, Juliette Thariat, et al.
European Journal of Dermatology : EJD|May 29, 2010
A three-year-analysis of fixed drug eruptions in hospital settings in FranceNesrine Brahimi, Emilie Routier, Nadia Raison-Peyron, et al.
The Journal of Investigative Dermatology|January 30, 2009
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized studyPascal Joly, Jean-Claude Roujeau, Jacques Benichou, et al.
The British Journal of Dermatology|October 4, 2023
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patientsRéda Chebani, Florian Lombart, Guillaume Chaby, et al.
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|March 5, 2025
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus VulgarisBillal Tedbirt, Estelle Houivet, Maud Maho-Vaillant, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
Blood|February 7, 2020
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedemaThibault Mahévas, Bertrand Arnulf, Jean-David Bouaziz, et al.
Pageof 5